These are the five worst-performing stocks in the Dow Jones Industrial Average as 2024 comes to a close

It’s been a great year for the stock market. However, not all stocks were winners, with some sectors performing better than others. Technology and utilities companies rose, while others such as real estate and health care performed less than expected.

So what are the five worst performers in Dow Jones Industrial Average (DJI: ^DJI) existing Blue arrows? Let’s take a look.

Boeing (NYSE: BA) It’s been a tough year. It started early when the stock price fell after the door panel on a Boeing plane passed Alaska Airlines Popped in mid-flight. Follow-up investigations revealed a workplace culture in which quality controls had become too lax. Boeing has appointed a new CEO, but a full turnaround could take years.

Nike (NYSE: NE) It has suffered this year as missteps under former CEO John Donahue (who was also ousted this year) led to falling sales and profits and market share losses to upstart competitors such as Ali Holding and Decker Hoka brand. Nike has also been criticized for moving away from brand marketing and wholesale relationships with chains such as Nike Foot locker. The strategy is expected to change under new CEO and company veteran Elliott Hill.

Merck (NYSE: MRC) It is one of many pharmaceutical stocks that have underperformed this year. The company has struggled to find growth beyond Keytruda, a cancer drug, as franchises such as the HPV vaccine Gardasil and diabetes drug Januvia declined due to weakness in Gardasil in China and competition for Januvia. Keytruda now accounts for nearly half of its revenue, although headwinds against other drugs have eroded profits.

Johnson & Johnson (NYSE: GING) It also declined this year as it faced headwinds related to lawsuits over its talc-based products, and profits fell due to legal costs and increased research and development expenses.

Like other healthcare stocks, Amgen (Nasdaq: AMGN) It missed the cyclical tailwinds that lifted the market broadly, and faced challenges with MariTide, a weight-loss drug that can be linked to loss of bone mineral density. Revenues from oncology therapies and existing products such as Enbrel also declined.

Have you ever felt like you’ve missed out on your most successful stock buying journey? Then you’ll want to hear this.

On rare occasions, our team of expert analysts issues a “Double Bottom” stock. Recommendation of companies they think are about to emerge. If you’re worried about missing your opportunity to actually invest, now is the best time to buy before it’s too late. The numbers speak for themselves:

The story continues